Rockefeller University biotech inventors at Arab Health Dubai will advance collaboration discussions with UAE stakeholders in the UAE biotech sector.
— Dr. Kambiz Shekdar, Rockefeller alumnus and biotechnology inventor.
NEW YORK, USA, January 28, 2023 /EINPresswire.com/ — Rockefeller University alumnus and Secondcell Bio CEO Dr. Kambiz Shekdar attended Arab Health in Dubai to raise funds for a new UAE joint venture in the UAE to discover and adapt Commercialization of 100 new drugs. Called Emirati Cell Bio™, the partnership is based on proprietary biotechnology derived from the Rockefeller University’s Nobel and King Faisal Prize-winning laboratory. These developments are based on the UAE’s aim to expand the country’s biotech sector.
Emirati Cell Bio™ represents an opportunity for scale-up, not start-up. The UAE Biotech Facility aims to discover, develop and commercialize 100 or more new medicines through standalone IPOs and/or collaborations with major pharmaceutical companies. Known as Chromovert®The IPO-enabling™ discovery engine has been successfully commercially proven in different usage domains and lines of business.
chameleon® For the discovery and development of a novel, non-addictive pain medication that is the subject of Chromocell Therapeutics’ IPO filing on January 11, 2023. The painkiller was fast-tracked by the FDA and featured at Gov. Chris Christie’s panel on the opioid epidemic at the White House as one of the few products to prepare for the catastrophe.
chameleon® Also used to discover and commercialize the first-ever natural saltiness enhancers and new natural sweeteners to reduce salt and sugar in the diet. Taste Research collaborates with the world’s leading food and beverage companies The Coca-Cola Company, Kraft Foods and Nestlé.From stopping pain to reducing salt and sugar in the diet, these different applications of the same underlying platform discovery engine demonstrate the breadth and scope of Chromovert® technology.
More than $100 million in private funding (and $0 in venture capital or US government grants) has been invested in pioneering accessible technologies.chameleon® Inventor Dr Shekdar is now transferring large-scale drug discovery technology to the UAE through Secondcell Bio.
Joint Venture’s Competitive Advantage Based on Proprietary Chromovert® Technology and opportunities to scale up in the UAE.High costs of scaling and entrenched team fears of obsolescence remain barriers to scaling®. As the UAE does not have a traditional pharmaceutical industry, a large-scale public-private partnership (PPP) involving UAE stakeholders can be leveraged to leapfrog the industry and achieve the national goal of expanding the biopharmaceutical industry.
Dr. Shekdar Seeks $50M in Seed Funding to Build Working Chromovert® UAE’s drug discovery “engine” and laboratory infrastructure. Seeking an additional $10-950 million to run the engine to produce 100 or more new drug candidates for commercialization within 3-5 years.In addition to continuous negotiations with the UAE sovereign wealth fund as a strategic partner, potential individual investors can also participate in the customized form of the innovative SAFE model of the US Y Combinator incubator
While Secondcell Bio is mainly focused on the drug discovery application of Chromovert®Non-pharmaceutical applications that do not require human clinical trials will also be pursued with faster overall commercialization timelines, including the discovery of natural volatiles to modulate the aroma of consumer products, similar to what has been done previously for Coca-Cola, Kraft and Nestle. Consumer preference for fragranced products is driven by smell and fragrance. However, the biology of human odor and aroma perception is mediated by more than 400 odorant receptors, compared to the biology of human taste, which involves 30 to 40 taste receptors, making traditional cell-based discovery approaches impossible. .chameleon® Physiological pathways that have been shown to enable such complex biology, the scale of investment in the UAE allows for the development of new consumer product applications (see “The nose, understanding the biology of the human sense of smell: new, all-natural fragrance ingredients; novel consumer fragrances Experience and Application”, Harry’s Cosmetology, 9th ed.).
UAE joint ventures aim to create multiple multi-billion dollar business entities. Drugmakers are estimated to rake in an average of $18.6 billion in global revenue per new drug. However, the industry currently has a high failure rate of 98% in the discovery and development of new drugs, indicating an urgent need for improvements at all stages of the process. High failure rates also drive up the average cost of manufacturing each new drug by more than $1.8 billion. Automated and improved Chromovert-enabled processes enable a paradigm shift: At less than the cost of producing one new drug, many drug discovery programs with a higher overall likelihood of success and cost-effectiveness will be implemented simultaneously to develop at least 100 new drugs each Each of these candidates could either conduct an IPO through its own dedicated entity and/or partner with Big Pharma for further development. Once established in the UAE for the first time, the same infrastructure may also be granted franchises such as Saudi Cell Bio™, India Cell Bio™, etc.
For more on the UAE’s growing biotech industry, see Dr. Shekdar’s first-hand account “From Oil to Medicine” in the January 2023 WestView News front page report in Manhattan, linked here: https://westviewnews.org /2023/01/17/From oil to medicine/James/
About CHROMOVERT® Technology & SECONDCELL BIO
Biological science deals with human cells. Cells that accurately mimic human disease are the basis for discovering new medicines. However, of the large number of cells designed to model disease, only a tiny minority are suitable. Detecting and isolating the best cells is difficult.chameleon® Facilitates the detection and purification of even extremely rare cells of interest. The platform technology works on any gene and on any cell, opening up new applications in flavor and drug discovery, biologics manufacturing, cell and stem cell therapies, and crop engineering.chameleon® Invented by Dr. Kambiz Shekdar in the laboratory of his late advisor and doctoral advisor, Dr. Gunter Blobel, MD, Professor at The Rockefeller University. Scientific publications on this technology are available at the following link: https://link.springer.com/article/10.1007/s10529-021-03101-5
Secondcell Bio is a life science company aiming to realize the full potential of Chromovert® Science and technology for human health.Company founded by Dr. Kambiz Shekdar, inventor of Chromovert® technology.
email us here
Visit us on social media:
Marwan Abdul Aziz, Director, Dubai Science Park